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Novel compound mutations in 
the mitochondrial translation 
elongation factor (TSFM) gene 
cause severe cardiomyopathy 
with myocardial fibro-adipose 
replacement
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Primary mitochondrial dysfunction is an under-appreciated cause of cardiomyopathy, especially when 
cardiac symptoms are the unique or prevalent manifestation of disease. Here, we report an unusual 
presentation of mitochondrial cardiomyopathy, with dilated phenotype and pathologic evidence of 
biventricular fibro-adipose replacement, in a 33-year old woman who underwent cardiac transplant. 
Whole exome sequencing revealed two novel compound heterozygous variants in the TSFM gene, 
coding for the mitochondrial translation elongation factor EF-Ts. This protein participates in the 
elongation step of mitochondrial translation by binding and stabilizing the translation elongation 
factor Tu (EF-Tu). Bioinformatics analysis predicted a destabilization of the EF-Ts variants complex with 
EF-Tu, in agreement with the dramatic steady-state level reduction of both proteins in the clinically 
affected myocardium, which demonstrated a combined respiratory chain enzyme deficiency. In patient 
fibroblasts, the decrease of EF-Ts was paralleled by up-regulation of EF-Tu and induction of genes 
involved in mitochondrial biogenesis, along with increased expression of respiratory chain subunits and 
normal oxygen consumption rate. Our report extends the current picture of morphologic phenotypes 
associated with mitochondrial cardiomyopathies and confirms the heart as a main target of TSFM 
dysfunction. The compensatory response detected in patient fibroblasts might explain the tissue-
specific expression of TSFM-associated disease.
Primary mitochondrial dysfunction is an under-appreciated cause of cardiomyopathy, especially when car-
diac symptoms are the unique or prevalent manifestation of disease. Homoplasmic mutations in mitochon-
drial (mt)-tRNAs are paradigmatic of the clinical elusiveness of mitochondrial aetiology. Patients develop 
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a cardiomyopathy with hypertrophic phenotype, which is often isolated (i.e. not associated with typical 
extra-cardiac features of mitochondrial disease) and can rapidly progress to heart failure1. The mitochondrial 
aetiology in these cases often represents an unexpected finding at cardiac transplant or autopsy, as typically 
described in families bearing the m.4300 A > G variant in the MTTI gene2. Useful clinical clues for identifying 
cardiomyopathies with an underlying pathogenic mechanism are maternal inheritance or the presence of other 
clinical signs, such as mild blood lactate increase, hearing loss, or subclinical myopathy3. A histochemical hall-
mark of mitochondrial cardiomyopathy is the presence of cytochrome c oxidase (COX)-deficient cardiomyocytes. 
Definitive diagnosis requires the demonstration of combined respiratory chain enzyme deficiency on cardiac 
muscle, which indicates a generalized defect in mitochondrial translation3, or a confirmed molecular genetic 
diagnosis. In recent years, the advent of high-throughput next generation sequencing has expanded the spectrum 
of genetic alterations that lead to mitochondrial cardiomyopathy (reviewed in4,5). In addition to mutations in 
the mitochondrial genome encoding mt-tRNAs, autosomal recessive pathogenic variants have been reported in 
nuclear genes encoding key proteins implicated in translation. These include structural mitoribosomal proteins; 
mt-aminoacyl-tRNA synthetases; mt-tRNA-modifying enzymes; and initiation, elongation and termination fac-
tors of translation (see for review6,7). These autosomally-driven mitochondrial disorders are usually associated 
with an early-onset, severe (often fatal) clinical course, with variable phenotypes. Cardiac specific presentations 
may occur, in the form of infantile hypertrophic cardiomyopathy8–12.
Here, we describe a case of mitochondrial cardiomyopathy with a severe dilated phenotype and pathologic 
features of biventricular fibro-adipose replacement in a 33-year-old woman who underwent cardiac trans-
plant. Whole exome sequencing revealed novel, compound heterozygous variants in TSFM [NM_001172697.1; 
MIM 604723], encoding the mitochondrial translation elongation factor (EF-Ts). A detailed molecular analysis 
revealed almost complete absence of the protein variant in the affected myocardium as compared to controls, 
confirming the pathogenic role of the identified mutations. Analysis of mutant fibroblasts suggests possible expla-
nations for the tissue specific expression of the disease.
Results
patients. Patients demographic data are summarized in Supplementary Table S1.
Clinical history of the index case. The index case was a 33-year-old female born at term to non-consanguineous 
healthy parents. She had a younger healthy sister. Pregnancy and delivery were uneventful with normal early 
psychomotor development. Since early childhood, gross- and fine-motor clumsiness and frequent falls were 
observed, followed by mild muscle weakness and reduced lower limb coordination. Cognitive function was nor-
mal. Genetic screening for Friedreich and spinocerebellar ataxia (SCA) genes had been performed, with neg-
ative results. Symptoms remained stable until age 27, when she referred to the Cardiomyopathies Unit of San 
Camillo-Forlanini Hospital of Rome because of worsening fatigue and dyspnoea. Rest 12-lead electrocardiog-
raphy showed sinus rhythm in absence of repolarization and depolarization abnormalities. Echocardiography 
revealed a mildly dilated left ventricle (LV), with increased wall ecoreflexibility (Fig. 1A), LV end-diastolic 
diameter (LVDD) of 51 mm and ejection fraction (EF) of 21%, consistent with dilated cardiomyopathy. Serum 
lactate level was slightly increased (3.70 mM; control <2.2 mM). Electromyography, electroneurography and 
neuro-ophtalmological analysis were normal. Despite medical therapy, LV function progressively decreased. At 
the age of 33 years, echocardiography showed a hypokinetic and dilated LV, LVDD of 54 mm, ventricular septum 
thickness of 10 mm, and EF of 15%. The patient underwent cardiac transplant a few months later.
Controls. Controls consisted of failing hearts (FH, n = 4) obtained from patients who underwent cardiac 
transplantation because of idiopathic dilated cardiomyopathy (DCM); and non-failing hearts (NFH, n = 4) 
obtained from donors which were unsuitable for transplantation for technical reasons (see Material and Methods 
section). All the explanted hearts were analysed at the Cardiovascular Pathology unit of Policlinico Umberto 
I. Morphological data and representative gross and histological pictures of both FH and NFH are provided in 
Supplementary Information (Supplementary Table S1 and Supplementary Fig. S1).
Morphologic analysis and diagnosis of mitochondrial cardiomyopathy. On external examina-
tion, the heart from the index case showed a globoid shape, with aneurysmal dilation of the anterior wall of 
the right ventricle (Fig. 1B). Coronary arteries were unremarkable. On short-axis section, both ventricles were 
dilated. There were multiple foci of myocardial fibro-adipose replacement, involving the anterior and posterior 
right ventricular wall and the infundibulum (with occasional transmural extension) and the subepicardial and 
midventricular layers of the left ventricular posterior wall (Fig. 1C). At histology, myocardial replacement was 
mostly fibrous in the left ventricle, and mostly adipose in the right ventricle. Patchy CD3+ lymphocytic infiltrates, 
without myocyte necrosis (Fig. 1D,E) were often detected in the surrounding myocardium (Fig. 1F). Residual 
cardiac myocytes appeared hypertrophic and showed vacuolated sarcoplasm filled with round-shaped orga-
nelles, consistent with mitochondria (Fig. 2A,B). Since fibro-adipose myocardial replacement is a typical feature 
of arrhythmogenic cardiomyopathy (ACM) due to inherited mutations in desmosomal proteins13,14, we looked 
by immunohistochemistry for reduced expression of plakoglobin at myocytes intercalated disks, which has been 
reported in ACM15,16 but did not detect any difference in the expression level of the protein as compared to con-
trols (Supplementary Fig. S2). On the other hand, ultrastructural analysis detected a marked intermyofibrillar 
mitochondrial proliferation (Fig. 2C), in agreement with the histologic features of cardiac myocytes, suggesting 
a mitochondrial aetiology. To verify this hypothesis, the histocytochemical reaction for sequential cytochrome c 
oxidase/succinate dehydrogenase (COX/SDH) was performed, revealing a mosaic pattern of COX-deficient cells, 
most marked in the left ventricle (Fig. 2D). Accordingly, biochemical analysis of mitochondrial respiratory chain 
activities performed on cardiac homogenate showed combined deficiency of Complex (C)-I (approximately 60% 
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of the control mean) and C-IV (below 20% of the control mean) (Fig. 2E). This feature was paralleled by reduc-
tion of the steady-state levels of selected C-I and C-IV subunits, while C-II, C-III and C-V subunits were spared 
(Fig. 2F).
Identification of TSFM mutations by whole-exome sequencing. To identify the genetic variants 
responsible for the observed cardiac phenotype we first performed sequence analysis of the complete mitochon-
drial genome, but all of the identified sequence variants corresponded to previously reported polymorphisms 
described in the MitoMAP compendium (www.mitopat.org, Jun 28th 2018); no pathogenic mtDNA variants 
were detected (Supplementary Table S2). Quantitation of mtDNA content in cardiac homogenate showed nor-
mal mtDNA copy number [mtDNA copy number per cell = 3353 versus 3197 ± 487 in age-matched controls 
(n = 7)]. Subsequently, whole exome sequencing was undertaken leading to the identification of two novel, het-
erozygous variants in the TSFM gene (NM_001172697.1): one frameshift mutation, c.408_409delGT p.(Leu-
137Glyfs*24) and a missense variant, c.505C > T p.(Leu169Phe) (Fig. 3A). TSFM encodes for a mitochondrial 
Figure 1. Morphologic features of explanted heart. (A) Echocardiographic long axis view at the time of 
diagnosis, showing a mildly dilated left ventricle (dashed double sided arrow) with an end diastolic diameter 
(LVDD) of 51 mm. Note the increased wall ecoreflexibility (asterisk). (B) Frontal view of the enlarged heart 
(transverse diameter 120 mm) with a depressed infundibulum consistent with aneurysmal dilation of the 
anterior wall of the right ventricle (asterisk). (C) Cross section of the heart showing biventricular enlargement 
(RV chamber diameter 50 mm; LV chamber diameter 55 mm). Foci of fibroadipose myocardial replacement are 
evident in the anterior (asterisk) and posterior right ventricular wall, and the subepicardial and midventricular 
layers of the left posterior wall (arrows). (D) Masson trichrome stain performed on a RV section shows 
abundant connective tissue (blue) replacing cardiac myocytes (red). Adipose tissue is indicated by arrows. 
Transmural fibroadipose replacement is indicated by asterisks. (Scale bar 250 μm). (E) Foci of scarring 
(showed in blue) are evident in the LV (Masson trichrome stain, scale bar 250 μm). (F) Patchy inflammatory T 
lymphocytic infiltrate are showed in brown (arrows), (immunohistochemical reaction with anti CD3 antibodies, 
scale bar 50 μm). RV = right ventricle; LV = left ventricle.
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translation elongation factor protein (EF-Ts) that catalyzes the exchange of guanine nucleotides on the translation 
elongation factor Tu (EF-Tu) during the elongation step of mitochondrial protein translation17. Mutations in 
this gene have been identified as a cause of autosomal recessive infantile-onset mitochondrial cardiomyopathy, 
encephalopathies with optic and/or peripheral neuropathy, ataxia and Leigh syndrome18–20. The c.408_409delGT 
p.(Leu137Glyfs*24) variant introduces a shift in the translation reading frame of the TSFM transcript, resulting 
in the introduction of a premature termination codon, and is therefore deemed to be pathogenic. The c.505C > T 
p.(Leu169Phe) variant is not listed on current SNP database (www.ncbi.nlm.nih.gov/SNP/) and has not been pre-
viously detected in large-scale sequencing studies (http://evs.gs.washington.edu/EVS/; http://exac.broadinstitute.
org/) to date. This variant predicts the exchange of a highly conserved leucine residue by phenylalanine, with this 
substitution likely to affect the stability of the EF-Ts/EF-Tu complex (see below); additionally, in silico analysis 
(Alamut software v2.7.1) provides additional support in favour of pathogenicity.
Orthogonal validation by Sanger sequencing confirmed the presence of the two variants in the proband. DNA 
from her father was not available; however, her healthy mother was shown to be heterozygous for p.(Leu169Phe) 
Figure 2. Morphological, biochemical and molecular evaluation of mitochondria on cardiac tissue. (A) 
Hypertrophic cardiac myocytes with vacuolated sarcoplasm in the left ventricle (Hematoxylin and eosin, 
scale bar 100 μm). (B) Vacuoles appeared filled with round-shaped organelles consistent with mitochondrial 
proliferation (asterisks) (Hematoxylin and eosin, scale bar 50 μm). (C) Ultrastructural analysis shows 
longitudinally arranged cardiac myocytes with clusters of interfibrillar mitochondria (IFM) causing 
displacement of myofibrils (MF). Mitochondria appear round-shaped and heterogeneous in size (uracyl acetate 
lead citrate). (D) Combined COX/SDH stain shows several isolated COX-deficient cardiomyocytes both in the 
RV and LV; this feature is more prevalent in the LV. (E) Biochemical analysis of mitochondrial respiratory chain 
enzyme activities performed on cardiac homogenate from the proband and controls. Enzyme activities are 
normalized to citrate synthase (CS) activity and expressed as percentage of controls (red: controls, blue: patient). 
(F) Western blot analysis of nuclear- and mitochondrial-encoded proteins performed on cardiac homogenate 
from the proband (P) and controls (C1, C2). RV = right ventricle; LV = left ventricle.
5Scientific RepoRts |          (2019) 9:5108  | https://doi.org/10.1038/s41598-019-41483-9
www.nature.com/scientificreportswww.nature.com/scientificreports/
Figure 3. Sequence analysis of TSFM. (A) Pedigree and chromatograms of the two identified mutations. Both 
mutations were confirmed to be heterozygous. The black circle indicates the proband, strike-through indicates 
deceased subject. (B) Multiple sequence alignment of the four human mitochondrial EF-Ts protein isoforms 
and the bovine homologue (Bt_EF-Ts), whose 3D structure is available from the PDB (PDB ID: 1XB2). Upper- 
and lower-case letters indicate residues present and absent, respectively, in the crystal structure of bovine EF-Ts 
and in the models of the human isoforms. Residues that differ from isoform 1 are italic and positions where 
the bovine template differs from isoform 1 are indicated by asterisks. Sites affected by mutations described in 
this work are indicated by arrows. Sequences are highlighted as follows: yellow, region encompassing the entire 
isoform 3 (residues 43–167); red, loop region only present in isoform 2 (residues 168–182); orange, isoform 
4 region following isoform 3 (residues 162–215, according to isoform 1 numbering); green, isoform 1 and 2 
region following isoform 4 (residues 216–325, isoform 1 numbering). (C) Conservation of leucine residues at 
positions 137 and 169 of EF-Ts isoform-1 in a few representative eukaryotic species. The results of an extensive 
conservation analysis over more than 3,900 species are shown in Supplementary Fig. S3 and discussed in the text.
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TSFM variant, while the p.(Leu137Glyfs*24) TSFM frameshift variant was not observed (Fig. 3A). The healthy 
sister of the proband did not carry either variant.
Bioinformatics analysis of the effect of mutations on EF-Ts structure. To evaluate the effects of the 
observed variants on the EF-Ts protein structure, a detailed bioinformatic analysis was undertaken. According to 
both the NCBI Gene (www.ncbi.nlm.nih.gov) and UniProt (http://www.uniprot.org/) databases, alternative splic-
ing of the TSFM gene encodes four protein isoforms (see Materials and Methods for UniProt and NCBI sequence 
identifiers). These isoforms are identical to one another in the N-terminal region (residues 1–161) and differ in 
the C-terminal region (Fig. 3B). Of the two mutations reported above, p.(Leu137Glyfs*24), which is followed by 
chain truncation, occurs in the conserved N-terminal region and, therefore, has the same sequence numbering in 
all isoforms. Conversely, the p.(Leu169Phe) mutation occurs in the variable C-terminal region, at position 169 in 
isoforms 1 and 4, and 190 in isoform 2. Isoform 3 is not affected by this mutation since it is only 167 residues long.
Conservation of the residues at mutated positions was investigated by building a multiple sequence align-
ment (MSA) comprising EF-Ts protein homologues from over 3900 different species. In this MSA, p.Leu137 is 
conserved in nearly 48% of the species, whereas Gly is nearly absent at that position; in no species residue 137 
is followed by truncation. Leu at position 169 (throughout the text we use the sequence numbering of isoform 
1 (having identifiers P43897-1 and NP_005717.3 in the UniProt and NCBI databases, respectively; see Material 
and Methods) is even more conserved, since it occurs in 60% of the sequences, followed by Ala (15%) and other 
hydrophobic, neutral or polar residues (i.e., Val, Phe, Ile, Met, Gln, Thr, Ser and Gly) with percentages between 
8% and 1% (Fig. 3C and Supplementary Fig. S3).
Building and analysis of homology models of all EF-Ts wild-type and mutant protein isoforms (Fig. 4A–D) 
allowed the structural role of the mutations and their effect on the interaction with EF-Tu to be investigated. The 
truncation of all isoforms following p.Leu137Gly mutation is likely to have a dramatic effect on the interaction 
with EF-Tu. Even if the residual part of the molecule remained folded as in the wild-type (Fig. 4B), the EF-Ts 
surface involved in interaction with EF-Tu would be greatly reduced (from about 1570 to 1075 Å2), resulting in 
weaker binding. In the wild-type model (Fig. 4A), p.Leu169 is tightly packed with a hydrophobic core comprised 
of the side-chains of residues Val141, Thr145, Leu164, Leu172, Leu182, Leu199 and Ala202. Replacement of 
Leu169 with the bulkier Phe in EF-Ts isoforms 1, 2 and 4 determines the establishment of unfavourable van der 
Waals contacts with surrounding residues (Fig. 4C,D). Release of these clashes is likely to require main-chain, as 
well as side-chain movements, and to involve a shift in the relative positions of helices H5, H6 and H7, where both 
Phe169 and residues making clashes with it are located (Fig. 4C). Since helices H5 and H7 are at the interface with 
EF-Tu, their movement is expected to reverberate on EF-Ts/EF-Tu interaction.
Marked decrease of EF-Ts and EF-Tu proteins in cardiac tissue from the proband. To confirm 
whether destabilization of the EF-Ts/EF-Tu complex was responsible for the cardiac phenotype, we analyzed the 
expression of EF-Ts and EF-Tu proteins and cDNA in myocardial samples from patient and controls. We also 
evaluated the expression of EF-G1 (GFM1 gene), a mitochondrial elongation factor that it is not supposed to 
interact directly with the EF-Ts/EF-Tu complex.
Both EF-Ts protein and cDNA were dramatically decreased in myocardium from the proband as compared 
with both FH and NFH, along with a reduction of EF-Tu protein. This last finding is in line with the likely desta-
bilizing effect of the mutations on the EF-Ts/EF-Tu complex, as already reported18. In contrast, protein and gene 
expression of EF-G1 were unchanged. A slight decrease of EF-Tu was also observed in FH versus NFH hearts 
(Fig. 5A,B and Supplementary Fig. S4).
Induction of mitochondrial biogenesis in mutant fibroblasts associated with decrease of EF-Ts 
but not EF-Tu proteins. To acquire some clues relating to the tissue-specific presentation of TSFM vari-
ants, we evaluated the expression of the EF-Ts/EF-Tu complex and the bioenergetic proficiency of skin-derived 
fibroblasts from the proband and three age-matched adult controls. Interestingly, although EF-Ts levels were 
decreased in patient fibroblasts, as in cardiac tissue, both EF-Tu protein and gene expression were up-regulated, 
while EF-G1 was unchanged as compared to controls (n = 3) (Fig. 5A,B and Supplementary Fig. S4).
Furthermore, mitochondrial biogenesis appeared to be activated, as demonstrated by the induction of 
essential genes involved in both mitochondrial transcription and replication (PGC1α, NRF1, TFAM and 
POLG), an increase in mtDNA copy number (Fig. 6A,B) and increased steady-state levels of selected nuclear 
and mitochondrial-encoded respiratory chain subunits (Fig. 6C). Accordingly, the rate of oxygen con-
sumption, a hallmark of bioenergetic proficiency, was unchanged after 96 hours incubation in glucose-free, 
galactose-supplemented medium (galactose medium), a condition forcing cells to rely on OXPHOS for ATP pro-
duction (Fig. 6D). Since a well-known activator of mitochondrial biogenesis is the increase in oxidative stress21, 
we measured the levels of hydrogen peroxide. These were slightly increased in mutant fibroblasts incubated 
24 hours in galactose medium, as compared with controls (Fig. 6E).
Discussion
Herein, we report an unusual presentation of mitochondrial cardiomyopathy, with dilated phenotype and patho-
logic evidence of biventricular fibro-adipose replacement, in a 33-year-old woman who underwent cardiac trans-
plant. The morphologic evidence of cardiac mitochondrial proliferation and the clinical history of mild ataxia 
suggested an underlying mitochondrial aetiology, which was confirmed by the demonstration of a combined 
defect of respiratory chain enzyme activities in the affected myocardium. Analysis of mtDNA was unremarkable, 
while whole exome sequencing revealed two novel compound heterozygous variants in highly conserved regions 
of the TSFM gene, encoding the mitochondrial translation elongation factor EF-Ts. This protein participates in 
the elongation step of mitochondrial protein translation by binding and stabilizing the translation elongation 
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factor Tu (EF-Tu) and promoting the formation of EF-Tu/GTP from EF-Tu/GDP22. Structural analysis of the 
homology models built for EF-Ts isoforms indicated a likely destabilizing effect of the mutations on EF-Ts/EF-Tu 
complex. Accordingly, the steady-state levels of both EF-Ts and EF-Tu proteins in the affected myocardium were 
dramatically decreased.
Mutations in the TSFM gene [i.e. the homozygous p.(Arg312Trp) change, in a subdomain of EF-Ts interacting 
with EF-Tu], have been previously demonstrated in infantile cases of severe hypertrophic cardiomyopathy with 
or without encephalomyopathy18,23, or liver failure24, leading to death in the first months of life. More recently, 
further TSFM pathogenic changes have been demonstrated in children with slowly progressing hypertrophic or 
dilated cardiomyopathy, who later developed neurological symptoms as the predominant manifestation of the 
disease (i.e. optic and/or peripheral neuropathy; ataxia; Leigh disease)19,20. In the present case, symptoms and sign 
of cardiac involvement manifested only in adulthood, characterized by fatigue and dyspnoea rapidly progressing 
to congestive heart failure, while a mild and stable form of ataxia was documented since infancy.
Our report confirms that the heart is a main target of TSFM dysfunction, both in children and adults, and 
extends the morphologic spectrum of mitochondrial cardiomyopathies. In fact, the finding of multiple foci of 
fibro-adipose myocardial replacement involving both ventricles had never been reported to our knowledge in 
primary mitochondrial dysfunction. Indeed, this is the pathologic hallmark of ACM, a heritable disease due to 
genetic defects in cardiac desmosomes, leading to heart failure and lethal arrhythmias, especially in young people 
Figure 4. Homology models of EF-Ts isoforms in complex with EF-Tu. (A) Mapping of EF-Ts protein isoforms 
on the homology model of isoform 2 in complex with EF-Tu. The protein main chain atoms are represented as 
cartoon and colour-coded as follows: blue, EF-Tu; yellow, EF-Ts isoform 3; yellow and orange, EF-Ts isoform 4; 
yellow, orange and green, EF-Ts isoform 1; yellow, orange, green and red, EF-Ts isoform 2. Leu137 and Leu169 
(according to isoform 1 numbering) are shown as sticks and coloured magenta. (B) Effect of the Leu137Gly 
mutation followed by truncation on all isoforms. Gly137 Cα atom is shown as a sphere and coloured magenta. 
(C) Effect of the Leu169Phe mutation on isoforms 1, 2 and 4. The side-chain of Phe169 (magenta) and of 
surrounding residues (cyan) are shown as sticks; to highlight them, the rest of the protein is made slightly 
transparent. (D) Close view of Phe169 (magenta) and of surrounding residues (cyan), both shown as sticks. 
Colour-coding is as in panel C.
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and athletes14. Although the original phenotype of ACM was characterized by a predominant right ventricle 
involvement (i.e. right ventricular dysplasia)25, clinical variants characterized by equivalent or even predominant 
involvement of the left ventricle (i.e., biventricular or left-dominant ACM), have been increasingly recognized26. 
Of note, patients with biventricular ACM may manifest clinically only in the advanced disease stage, with heart 
failure in the absence or presence of ventricular arrhythmias and may be incorrectly diagnosed as having idio-
pathic DCM14. In the present case, mitochondrial aetiology was suggested by the marked mitochondrial prolifer-
ation within cardiac myocytes and the anamnestic report of mild neurological manifestations.
Although a full understanding of the pathogenesis of ACM is currently lacking, it is believed that impairment 
of desmosomal assembly causes the translocation of the desmosomal protein plakoglobin from the sarcolemma 
to the nucleus, where it may induce a gene transcriptional switch from myogenesis to lipogenesis14. Interestingly, 
studies on induced pluripotent stem cells (iPSCs)-derived cardiomyocytes showed an overall depressed energy 
metabolism in ACM, characterized by dominant glucose utilization and reduction of fatty acid oxidation, similar 
to what is usually observed in mitochondrial disease27. Accordingly, our findings provide evidence that metabolic 
derangement may play a role in the development of an “ACM-like phenotype”. It is noteworthy that ACM has 
been described sporadically in association not only with desmosomal proteins but also with neuromuscular dis-
orders, such as myofibrillar myopathies or myotonic dystrophy28.
An interesting finding of our work is related to the different behaviour of EF-Tu expression in the affected 
myocardium and skin-derived fibroblasts from the proband. In fact, in the myocardium EF-Tu levels were 
severely reduced, in agreement with previous observations, which led to the suggestion that destabilization of 
EF-Ts/EF-Tu complex leads to increased turnover of its components and decreased steady-state levels of both 
factors18. In contrast, marked decrease of EF-Ts was associated with an up-regulation of EF-Tu in mutant fibro-
blasts. Interestingly, previous reports showed that forced overexpression of EF-Tu in cells obtained from carriers 
of pathogenic TFAM mutations is able to rescue the EF-Ts defect18. In line with this last observation, bioener-
getic proficiency of fibroblasts from the proband appeared within normal limits, even under stressful conditions 
(i.e. galactose medium), as demonstrated by the oxygen consumption rate. The over-expression of EF-Tu was 
paralleled by the overall activation of mitochondrial biogenesis, a well-known compensatory phenomenon in 
mitochondrial disorders29, possibly triggered by the increased production of oxygen species21. Thus, the induction 
of an adaptive response involving mitochondrial biogenesis and transcriptional upregulation of EF-Tu is able to 
reduce the penetrance of the TSFM mutations in fibroblasts. This phenomenon does not occur (or is ineffective) 
Figure 5. Expression of EF-Ts and EF-Tu on cardiac tissue and fibroblasts. (A) Left: Representative western 
blot images of EF-Ts, EF-Tu and EF-G1 proteins performed on extracts of heart homogenate from patient (P), 
and controls [i.e. non failing (NFH) and failing heart (FH)]. For each protein the blots are cropped from the 
same gel. Full-length blots are shown in Supplementary Fig. S5. Right: western blot images of EF-Ts, EF-Tu 
and EF-G1 proteins performed on fibroblasts derived from patient (P) and controls (i.e. wild-type donors, C). 
Experiments were performed in triplicate.(B) Gene expression analysis of TSFM, TUFM and GFM1 performed 
on cardiac tissue from P, NFH and FH (left), and from patient (P) and controls (C) fibroblasts (right). Data are 
expressed as mean ± SEM from three separate experiments. **p < 0.01 for FH versus NFH (umpaired t test).
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in cardiac tissue, in line with previous reports pointing to the impaired mitochondrial biogenesis as a main player 
in the progression to heart failure30,31. In agreement with this suggestion, EF-Tu levels were mildly although sig-
nificantly reduced also in non-mitochondrial failing hearts.
The ability of increased EF-Tu levels, either due to up-regulation or induced over-expression, to compen-
sate for a reduction in the levels of mutated EF-Ts, is reminiscent of the widely documented ability of several 
mt-aminoacyl-tRNA synthetases (aaRSs) to “rescue” defects associated with point mutations in cognate and, 
in some cases, non-cognate, mt-tRNAs (see for a Review32). In the case of mutations in mt-tRNAs, as well as 
EF-Ts, the rescuing effect has been observed both as a consequence of mt-aaRSs up-regulation and induced 
over-expression32. These observations suggest that when a protein involved in mitochondrial protein synthesis is 
mutated, increasing the levels of one of its interaction partners might be a general mechanism to prevent impair-
ments in this essential cellular process.
In conclusion, our report provides evidence about TSFM dysfunction as a cause of mitochondrial cardiomyo-
pathy both in infants and adults, thus extending the array of morphologic phenotypes associated with mitochon-
drial cardiomyopathies and highlights the role of metabolic derangements in the development of an ACM-like 
phenotype. Observations on mutant fibroblasts suggest possible explanations for the tissue specific expression of 
TSFM-associated disease, which may be extended to other mitochondrial translation disorders.
Figure 6. Fibroblasts molecular and biochemical phenotype. (A) Expression levels of genes involved in 
mtDNA transcription and replication in fibroblasts from the proband (P) and controls (C). Data are expressed 
as mean ± SEM from three separate experiments. (B) Amount of mtDNA, expressed as mtDNA/nuclear DNA 
ratio, in fibroblasts from the proband (P) and controls (C) maintained in galactose medium for 96 hours. Data 
are expressed as mean ± SEM from three separate experiments. (C) Western blot analysis of nuclear- and 
mitochondrial-encoded proteins on mutant fibroblast and two controls. (D) Rate of oxygen consumption in 
fibroblasts from proband (P) and control (C) incubated for 96 hours in galactose medium. Values obtained in 
galactose medium are normalized to the value obtained in glucose medium. Data are expressed as mean ± SEM 
from three separate experiments. (E) Levels of hydrogen peroxide in fibroblasts from proband (P) and control 
(C) incubated for 24 hours in galactose medium. Values obtained in galactose medium are normalized to the 
value obtained in glucose medium. Data are expressed as mean ± SEM from three separate experiments.
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Materials and Methods
patients. The work described has been carried out in accordance with The Code of Ethics of the World 
Medical Association (Declaration of Helsinki) and conformed to Sapienza University of Rome Ethical Committee 
protocols. All studies were undertaken with written informed patients consent. Collection and experiments with 
human-derived fibroblast have been approved from Sapienza University of Rome Ethical Committee (Prot. 
358/16). Non-failing, myocardial samples (n = 4) were obtained from donors hospitalized at Policlinico Umberto 
I of Rome, which were unsuitable for transplantation for technical reasons. Both the proband and failing heart 
(n = 4) were obtained from unrelated patients who underwent cardiac transplantation because of idiopathic DCM 
at Department of Cardiac Surgery and Transplantation of San Camillo-Forlanini Hospital of Rome. Myocardial 
samples were referred to the Cardiovascular Pathology Unit of Policlinico Umberto I for diagnostic purposes 
and examined following our routine diagnostic work-up1 and, accordingly to the rules of our local Committee, 
approval was waived. Skin derived fibroblast’s (n = 3) were obtained from age-matched volunteers.
Histology, histochemistry and respiratory chain enzyme biochemistry on heart tissue. Immediately 
after explant, hearts (from proband and controls) were weighed and photographed. Myocardial samples were obtained 
from multiple sites in both ventricles and were either processed for routine histology, or snap frozen in liquid nitro-
gen–chilled isopentane for histochemical, biochemical, and molecular studies, according to a standardized protocol1,33.
Hematoxylin-eosin and Masson trichrome stains were performed on multiple paraffin sections from both 
ventricles and the septum. To assess mitochondrial respiratory chain function, sequential COX and SDH reac-
tions on frozen sections from the left and right ventricles were performed as described1. For ultrastructural 
analysis samples were fixed in glutaraldehyde (2.5% in phosphate buffer), postfixed in osmium tetroxide, and 
embedded in epoxy resin (Epon 812). Ultrathin sections (100 nm) were observed after standard Reynold staining 
with a Zeiss EM 10 TEM equipped with digital image data processing software (DigitalMicrograph 3.4TM; Gatan, 
Munchen, Germany).
Biochemical analysis of individual mitochondrial respiratory chain complexes was performed on frozen car-
diac muscle homogenates, as described previously34. Specific enzyme activities were normalized to that of citrate 
synthase, a marker of mitochondrial mass.
Mitochondrial DNA analysis. Total DNA was isolated from heart tissue and fibroblasts using Wizard 
Genomic DNA Purification Kit (Promega, Madison, WI, USA). The total amount of mtDNA was calculated by 
quantitative real-time PCR (AB 7500 Fast, Applied Biosystems, Warrington, UK). Briefly, a mtDNA fragment (nt 
4625–4714; GenBank reference NC_012920.1) and a nuclear DNA fragment (FasL gene) were amplified using 
a TaqMan-MGB probe system. The amount of mtDNA relative to nuclear genomic DNA was evaluated with the 
comparative Ct method (2−ΔCt), where ΔCt = Ct mtDNA−Ct nuclear DNA35.
The entire mitochondrial genome was amplified and sequenced in a series of overlapping fragments by using 
BigDye terminator chemistries on an Applied Biosystem 3100 automated sequencer (Applied Biosystems)35. All 
sequences were directly compared with the revised Cambridge reference sequence for human mtDNA (GenBank 
accession no. NC_012920.1).
By using shifted primer sets within the major arc of human mtDNA, heart tissue DNA was tested for single, 
large-scale mtDNA deletions as described previously36.
Whole Exome Sequencing. Whole exome sequencing of heart DNA was conducted using the BCM HGSC 
CORE exome capture design (52 Mb, NimbleGen) and with paired-end sequencing on an Illumina HiSeq. 2500 
to a 100X average coverage. Bioinformatic analyses were conducted as previously described37. Single nucleotide 
variants (SNVs) and small insertions and deletions (InDels) were scored by GATK38. Quality control filtering of 
variants was based on coverage, strand bias, mapping quality, and base quality. Custom Perl scripts were used 
to annotate variants as previously described37,39. Algorithms used for prediction of potential functional conse-
quences of variants included CADD40, SIFT41 and PolyPhen242, Genomic Evolutionary Rate Profiling (GERP)43, 
and PhyloP44.
Cell culture. Fibroblasts were cultured in Dulbecco’s modified Eagle’s medium (DMEM), supplemented 
with 4.5 g/l D-glucose, 10% fetal bovine serum (FBS), 2 mM L-glutamine, 100 U/ml penicillin and 100 mg/ml 
streptomycin (referred to as glucose medium) in a humidified atmosphere of 95% air and 5% CO2 at 37 °C. A 
subset of experiments was performed in parallel either in glucose medium or in glucose free DMEM, supple-
mented with 10% dialyzed FBS (dFBS), 5 mM galactose and 110 mg/ml sodium pyruvate (referred to as galactose 
medium).
Oxygen consumption. Oxygen consumption was measured in treated and untreated intact cells (2–3 × 106) 
using a Clark-type oxygen electrode (Hansatech, Norfolk, UK) in 1 ml DMEM lacking glucose and supplemented 
with 10% sodium pyruvate, as described previously45.
Reactive oxygen species evaluation. Levels of hydrogen peroxide (H2O2) were measured by lumines-
cence assay using a ROS-Glo™ H2O2 Assay (Promega), according to the manufacturer’s protocol as previously 
described46. Briefly, a number of 1 × 104 cells were plated in a 96-well white cell culture plate and incubated 
overnight in glucose or galactose medium. After 24 hours medium was supplemented with H2O2 Substrate 
Dilution Buffer containing ROS-Glo™ H2O2. After 2 hours incubation, ROS-Glo™ Detection Solution was added 
and the plate was incubated for 20 min at room temperature. Luminescence was determined with a GloMax® 
Multi + Luminometer. The average RLU of triplicate samples were calculated.
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Gene expression analysis by quantitative real-time PCR. Gene expression experiments were 
performed on cardiac tissue from patient and controls. As controls we used both non-failing heart that were 
unsuitable for transplantation for technical reasons (NFH, n = 4), and failing heart with DCM obtained from 
transplant procedure (FH, n = 4). In addition, skin-derived fibroblasts from the proband and three age-matched 
controls were analyzed. Total RNA was isolated using SV Total RNA isolation kit (Promega) and measured 
with a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA). Total RNA 
(0.1–1 mg) was reverse-transcribed to cDNA using random hexamer primers. The relative expression levels of 
TSFM, TUFM, GFM1, PGC1α, TFAM, POLG and NRF1 were evaluated by using TaqMan probe chemistry and 
inventoried and custom FAM-labeled TaqMan MGB probes (Applied Biosystems), according to the manufactur-
er’s instructions. In all samples, the relative expression of each target gene was evaluated as compared with the 
mean of controls using the comparative threshold cycle (ΔCt) method. All values were normalized for the house-
keeper glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene. Each experiment was performed in triplicate.
Western blot and immunohistochemical analysis. For Western blot analysis, cells were rinsed twice 
with ice-cold PBS, lysed in ice-cold RIPA buffer [50 mM Tris–HCl pH 8, 150 mM NaCl, 1% NP-40, 0.5% sodium 
deoxycholate, 1% sodium dodecyl sulfate (SDS), 1 mM phenylmethylsulfonyl fluoride, 10 mg/ml aprotinin, 
10 mg/ml leupeptin and 10 mg/ml pepstatin] and centrifuged at 10,000 g for 10 min at 4 °C. Protein concentra-
tion was measured by bicinchoninic acid (Beyotime Biotechnology, Haimen, China). Equal amounts of protein 
(50 mg) were separated by 12% SDS–PAGE and transferred into a nitrocellulose membrane (Millipore, Bedford, 
MO, USA). Primary antibodies were visualized using horseradish peroxidase-conjugated secondary antibodies 
(Dako, Glostrup, Denmark). Signals were detected by enhanced chemiluminescence (Amersham Biosciences, 
UK). The band intensities of western blots were analyzed by using NIH ImageJ (http://rsb.info.nih.gov/ij/).
The following primary antibodies were used: rabbit polyclonal antibody anti-mt EF-Ts (PA5-27652, Thermo 
Scientific, Rockford USA); rabbit polyclonal antibody anti-mt EF-Tu (PA5-27511, Thermo Scientific, Rockford 
USA); rabbit polyclonal antibody anti-mt EF-G1 (PA5-57049, Thermo Scientific, Rockford USA); rabbit pol-
yclonal antibody anti-GAPDH (PA1-16777, Thermo Scientific, Rockford USA); mouse monoclonal antibody 
anti-SDHA (ab14715; Abcam); mouse monoclonal antibody anti-ATP5A (ab110273; Abcam); mouse monoclo-
nal antibody anti-MT-COI (COX1, ab14705; Abcam); mouse monoclonal antibody anti-NDUFB8 (ab110242; 
Abcam); mouse monoclonal antibody anti-CORE 2 (ubiquinone: cytochrome c reductase core protein 2; 
ab110252; Abcam); mouse monoclonal antibody anti-Porin (ab14734; Abcam).
Analysis of TSFM gene product sequence and three-dimensional (3D) structure. The sequences 
of the four protein isoforms encoded by the TSFM gene were downloaded from the UniProt Knowledgebase47 
with UniProt IDs P43897-1, P43897-2, P43897-3 and P43897-4, respectively (corresponding to NCBI IDs: 
NP_005717.3, NP_001166167.1, NP_001166166.1 and NP_001166168.1, respectively), and aligned to one 
another (Fig. 3) using the multiple sequence alignment program ClustalO48.
The full MSA of members of the EF-Ts protein family (Pfam ID: PF00889) was downloaded from the Pfam 
database49. This alignment encompasses the region 116-274 of EF-Ts isoform 1 and the homologous regions from 
over 5,000 family members. Sequences that were incomplete at positions 119 and 229, corresponding to 137 and 
169 of EF-Ts isoform 1, were eliminated from the downloaded alignment. The MSA thus obtained, comprising 
over 3,900 sequences from different species, was used to calculate the frequency of occurrence of each residue at 
positions 119 and 229 (Supplementary Fig. S3).
A molecular model (Fig. 4) was built for each of the four EF-Ts isoforms by homology modelling, using 
the program SwissModel (https://swissmodel.expasy.org/). The template used for all isoforms was the 
three-dimensional (3D) structure of Bos taurus mt EF-Ts (chain B, residues 56-338) in complex with EF-Tu 
(chain A, residues 44–452), experimentally determined by X-ray crystallography, which was downloaded from 
the Protein Data Bank50 (PDB ID: 1XB2; Resolution = 2.20 Å). Model visualization and analysis were performed 
using SwissPDBViewer51 and PyMol (http://www.pymol.org/). Residues were defined to be in contact with 
Leu169 if they have at least one atom at a distance ≤4.5 Å from one atom of Leu169. The EF-Ts surface in contact 
con EF-Tu was calculated with Naccess52.
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